Provided by Tiger Trade Technology Pte. Ltd.

Erasca, Inc.

16.22
+0.52003.31%
Volume:5.26M
Turnover:86.64M
Market Cap:5.67B
PE:-16.70
High:17.25
Open:15.37
Low:15.37
Close:15.70
52wk High:24.28
52wk Low:1.53
Shares:349.76M
Float Shares:291.15M
Volume Ratio:3.17
T/O Rate:1.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9710
EPS(LYR):-0.4393
ROE:-78.25%
ROA:-21.39%
PB:15.68
PE(LYR):-36.93

Loading ...

Erasca - Plans Registration-enabling Lung Cancer Trial in H1 2027; Phase 3 Pancreatic Cancer Trial in 2027

THOMSON REUTERS
·
Jul 14

Erasca Notifies Availability of Press Release on Updated Phase 1 Eras-0015 Data and Trial Plans

Reuters
·
Jul 14

Erasca initiated with Early Stage Biotech at Goldman Sachs

TIPRANKS
·
Jul 13

Robinhood and 4 More Stocks That were Just Added to This Firm's 'Top Picks' List

Dow Jones
·
Jul 02

Robinhood and 4 More Stocks That were Just Added to This Firm's 'top Picks' List

Dow Jones
·
Jul 02

Is Erasca’s (ERAS) Shift Into Russell Growth Indexes Reframing Its Core Investment Story?

Simply Wall St.
·
Jul 02

Erasca Holds Annual Shareholder Meeting

Reuters
·
Jul 01

Revolution Medicines Faces 'Uphill Battle' in Potential Patent Claim Against Erasca, RBC Says

MT Newswires Live
·
Jun 26

Erasca (ERAS) Could Be 40% Below Fair Value On Lawsuit And Trial Risk

Simply Wall St.
·
Jun 26

Verastem Says VS-7375 Trial Data Shows Anti-Tumor Activity in Advanced Solid Tumors

MT Newswires Live
·
Jun 24

Verastem says KRAS G12D inhibitor VS-7375 shows early activity in Phase 1/2 TARGET-D 101 trial across solid tumors

Reuters
·
Jun 24

Erasca, Inc. Faces Federal Securities Lawsuit Over Alleged Misleading Drug Comparisons and Concealed Intellectual Property Risks

TIPRANKS
·
Jun 16

Analysts Conflicted on These Healthcare Names: TransMedics Group (TMDX), Erasca (ERAS) and Incyte (INCY)

TIPRANKS
·
Jun 09

Erasca Shares Rise After BofA Upgrade

MT Newswires Live
·
Jun 05

Erasca Sees More Balanced Outlook as Early RAS Data Support Clinical Activity, BofA Says

MT Newswires Live
·
Jun 04

BofA Securities Upgrades Erasca to Neutral From Underperform, Adjusts Price Target to $16 From $9

MT Newswires Live
·
Jun 04

BeyondSpring names Min Qiu CEO in leadership transition effective July 1, 2026

Reuters
·
Jun 04

Erasca : Bofa Global Research Raises Price Objective to $16.00 From $9.00

THOMSON REUTERS
·
Jun 04

Erasca : Bofa Global Research Raises to Neutral From Underperform Rating

THOMSON REUTERS
·
Jun 04

Erasca Raised to Neutral From Underperform by B of A Securities

Dow Jones
·
Jun 04